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Objectives The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome
(ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary
intervention (PCI).
Background Newer P2Y12 inhibitors like prasugrel and ticagrelor provide stronger platelet inhibition compared with clopi-
dogrel. Both agents are efficacious in patients with HTPR while on clopidogrel, but direct comparison between
them has not yet been reported.
Methods In a prospective, single-center, single-blind study, 44 (of 139 screened, 31.7%) ACS patients with HTPR while on
clopidogrel 24 h post-PCI were randomized to either ticagrelor 90 mg twice daily or prasugrel 10 mg once daily
for 15 days with a crossover directly to the alternate treatment for another 15 days. HTPR was defined as plate-
let reactivity units (PRU) 235 as assessed by the VerifyNow P2Y12 function assay.
Results The primary endpoint of platelet reactivity at the end of the 2 treatment periods was lower for ticagrelor (32.9
PRU, 95% confidence interval [CI]: 18.7 to 47.2) compared with prasugrel (101.3 PRU, 95% CI: 86.8 to 115.7)
with a least squares mean difference of –68.3 PRU (95% CI: –88.6 to –48.1; p  0.001). The secondary end-
point of HTPR rate was 0% for ticagrelor and 2.4% for prasugrel (1 of 42, p  0.5). No patient exhibited a major
bleeding event at either treatment group.
Conclusions In patients with ACS exhibiting HTPR while on clopidogrel 24 h post-PCI, ticagrelor produces a significantly
higher platelet inhibition compared with prasugrel. (Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
After Percutaneous Coronary Intervention; NCT01360437) (J Am Coll Cardiol 2012;60:193–9) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.050In acute coronary syndrome (ACS) patients undergoing
percutaneous coronary intervention (PCI), a high on-
treatment platelet reactivity (HTPR) while on clopidogrel is
associated with adverse events (1–3). Newer P2Y12 inhib-
itors, such as prasugrel and ticagrelor, are accompanied by a
stronger and more consistent, compared with clopidogrel,
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with the observed favorable clinical effect of prasugrel and
ticagrelor when compared with clopidogrel in the TRITON–
TIMI 38 (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis In Myocardial Infarction 38) and PLATO
(PLATelet inhibition and patient Outcomes) trials, respec-
tively, though with increased risk of bleeding (13,14).
In pharmacodynamic studies, in post-PCI and in chronic
coronary artery disease (CAD) patients exhibiting HTPR,
prasugrel was more effective than a double maintenance
dose of clopidogrel in reducing platelet reactivity (PR),
whereas in stable CAD patients with HTPR following a
300-mg clopidogrel loading dose, ticagrelor therapy was
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inhibition compared with clopi-
dogrel (15–17). In the aforemen-
tioned studies, a very low rate of
HTPR was found following
treatment with either prasugrel
or ticagrelor. Therefore, ACS
patients undergoing PCI and ex-
hibiting HTPR while on clopi-
dogrel might be the ideal candi-
dates for treatment with either
ticagrelor or prasugrel. However,
no direct clinical or pharmacody-
namic comparison between these
2 agents has yet been reported.
In the present study, we aimed
to directly compare the pharmacodynamic action of ticagre-
lor with prasugrel in ACS patients exhibiting HTPR while
on clopidogrel.
Methods
Study protocol. We performed a prospective, randomized,
single-center, single-blind, investigator-initiated, crossover
study to compare platelet inhibition by ticagrelor 90 mg
twice daily versus prasugrel 10 mg once daily in patients
with ACS and HTPR while on clopidogrel post-PCI.
Consecutive ACS patients undergoing PCI with stent
implantation in our institution were considered for PR
assessment at 24 h following the procedure. Patients were
excluded if they had periprocedural IIb/IIIa inhibitors
administration, a history of stroke/transient ischemic attack,
bleeding diathesis, chronic oral anticoagulation treatment,
loading with different than clopidogrel antiplatelet agent,
contraindications to antiplatelet therapy, PCI or coronary
artery bypass grafting3 months, hemodynamic instability,
platelet count 100,000 l, hematocrit 30%, creatinine
clearance 30 ml/min, severe hepatic dysfunction, use of
strong CYP3A inhibitors or inducers, increased risk of
bradycardia, and severe chronic obstructive pulmonary
disease.
At the time of PCI, clopidogrel-naive patients and those
on clopidogrel 75 mg for 7 days without initial loading
dose received a 600-mg clopidogrel. Patients on clopidogrel
7 days but with 300-mg loading or those on clopidogrel
for 7 days did not receive any additional loading. All
patients received an intra-arterial dose of 70 international
units (IU)/kg heparin. After PCI, all patients received
aspirin 100 mg/day indefinitely.
Patients with HTPR (as defined subsequently) were
randomized (day 0) in a 1:1 ratio using computerized
random-number generation by an independent investigator
to ticagrelor 90 mg twice daily or prasugrel 10 mg once
daily, until day 15 post-randomization. A visit 15  2 days
was performed for PR measurement and safety evaluation,
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CAD  coronary artery
disease
CI  confidence interval
HTPR  high on-treatment
platelet reactivity
PCI  percutaneous
coronary intervention
PR  platelet reactivity
PRU  platelet reactivity
unit(s)with the blood sample being obtained 2 to 4 h after the laststudy drug dose, followed by crossover directly to the
alternate therapy for an additional 15 days without an
intervening washout period. Compliance to antiplatelet
therapy was assessed by interview and tablet counting. At
day 30  2, patients returned for the clinical and laboratory
assessment as done on the day 15 visit. Physicians and
operators who performed platelet function testing were
blinded as to the actual drug used, whereas an independent
physician monitored bleeding and adverse event data. Dys-
pnea was assessed on a 5-point Likert scale. A flow chart
diagram of the study is shown in Figure 1.
Platelet function assay. Peripheral venous blood samples
were drawn in a fasting state with a loose tourniquet
through a short venous catheter inserted into a forearm vein.
The first 2 to 4 ml of blood was discarded to avoid
spontaneous platelet activation, and blood was collected in
3.2% citrate (1.8-ml draw plastic Vacuette tubes, Greiner,
Monroe, North Carolina). Platelet-function testing was
performed with the VerifyNow (Accumetrics Inc., San
Diego, California) point-of-care P2Y12 function assay. A
value 235 platelet reaction units (PRU) was considered as
an indication of HTPR based on a previous investigation,
linking the cutoff point to post-PCI ischemic risk (18).
Endpoints. Endpoints were pre-specified in the study pro-
tocol and statistical analysis plan. The primary endpoint was
PR assessed at the end of the 2 (pre-crossover and post-
crossover) study periods. The HTPR rate during the same
periods was a secondary endpoint. Bleeding (major, minor,
or minimal according to Thrombolysis In Myocardial In-
farction [TIMI] criteria) and major adverse cardiovascular
events (cardiovascular death, myocardial infarction, and
stroke) were evaluated during the pre- and post-crossover
period.
Sample size calculation. We hypothesized that ticagrelor
90 mg twice daily would result in a PR absolute difference
of 50 PRU compared with prasugrel 10 mg once daily (with
the assumption that the within-patient standard deviation
of the response variable is 60). Choosing a power of 95%
and a 2-sided alpha level of 0.05, at least 40 patients in total
were required to reach statistical significance based in the
previous assumptions.
Statistical analysis. Categorical data is presented as fre-
quencies and group percentages, and continuous data as
mean  SD. Two-sample t test and the Fisher exact test
were used for comparison of continuous and categorical
data. Only patients who successfully completed at least 1
period of the study were considered for analysis. The
primary study endpoint was analyzed via a mixed linear
model, adjusting for period, treatment sequence (carryover),
and treatment effect (fixed factors), with patient indicator as
random effect and PR at baseline as a covariate. Least-
squares estimates of the mean difference are presented, with
95% confidence intervals (CIs) and a 2-sided p value for the
treatment effect. Separate analyses of covariance were con-
ducted for the pre- and post-crossover period with treat-
ment as fixed effect and PR at baseline as a covariate. The
p
F
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for subjects with both day 15 and day 30 data available. All
tests were 2-tailed and statistical significance was considered
for p values 0.05. Analyses were performed using SPSS
for Windows (version 16.0, SPSS Inc., Chicago, Illinois).
Bleeding events and major adverse cardiac events are re-
ported in a descriptive manner.
The study was conducted according to the principles of
the Declaration of Helsinki and was approved by the ethics
committee of the University Hospital of Patras, Greece. All
patients gave written informed consent.
Results
Of 139 patients with PR assessment, 44 (31.7%) were
identified to have HTPR while on clopidogrel and were all
randomized. Until day 15, side effects leading to study drug
discontinuation occurred in 1 patient, leaving 43 patients
available to test the study hypothesis. Baseline characteris-
tics of randomized patients are shown in Table 1. There was
no difference in patients’ demographic characteristics be-
tween groups. The primary endpoint was significantly lower
for ticagrelor (32.9 PRU, 95% CI: 18.7 to 47.2) compared
with prasugrel (101.3 PRU, 95% CI: 86.8 to 115.7) with a
least squares mean difference of –68.3 PRU (95% CI:
88.6 to 48.1; p  0.001) (Table 2). Data for the
re-crossover and post-crossover periods are shown in
Figure 1 Study Flow Chart
Of 139 patients with platelet reactivity assessment, 44 (31.7%) were identified
15, side effects leading to study drug discontinuation occurred in 1 patient, le
unit(s).igure 2. No period or carryover effect was found. The nsecondary endpoint of HTPR rate was 0% for ticagrelor and
2.4% for prasugrel (1 of 42, p  0.5). Individual PR values
according to treatment and baseline PR quartiles are de-
picted in Figure 3.
No patient exhibited a major adverse cardiovascular event
or a major bleeding event at either treatment group. Two
patients during the first period developed allergic reactions
under ticagrelor, leading to study drug discontinuation in 1
of them, 4 patients (2 under prasugrel and 2 under ticagre-
lor) reported minimal bleeding events, 2 patients both under
ticagrelor reported dyspepsia, and 4 patients (all under
ticagrelor) reported a mild new-onset/worsening dyspnea.
Discussion
In this first direct pharmacodynamic comparison of ticagre-
lor with prasugrel in ACS patients exhibiting HTPR while
on clopidogrel post-PCI, we have demonstrated that ti-
cagrelor provides stronger than prasugrel platelet inhibition.
However, both agents effectively treated the phenomenon of
HTPR in our population.
Pharmacodynamic studies. Platelet inhibition substudies
of the pivotal TRITON–TIMI 38 and PLATO trials have
been previously reported. In 31 patients, mean maximum
light transmittance aggregometry response (adenosine
diphosphate 20 M maximal platelet aggregation) was
9.9% and 55.2% with prasugrel and clopidogrel mainte-
ve high on-treatment platelet reactivity and were all randomized. Until day
43 patients available to test the study hypothesis. PRU  platelet reactivityto ha
avingance doses, respectively (19). In 69 patients on mainte-
et react
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ticagrelor 90 mg twice daily, mean maximal platelet aggre-
gation was 28% for ticagrelor and 44% for clopidogrel.
Using the VerifyNow assay, the respective values were 30
PRU and 215 PRU (12). It seems therefore that in separate
trials, the antiplatelet potency of ticagrelor was similar to
prasugrel (platelet inhibition ranging between 60% and
70%), compared with the approximately 40% to 45% plate-
Random Patient DemographicTable 1 Random Patient Demographic
T
Male
Age, yrs
Body mass index, kg/m2
Dyslipidemia
Hypertension
Diabetes mellitus
Smoking
Family history of CAD
Prior myocardial infarction
Prior coronary artery bypass graft
Prior percutaneous coronary intervention
Peripheral arterial disease
Medication
Statins
Proton pump inhibitors
Beta-blockers
Nitrates
Calcium-channel blockers
Angiotensin-converting enzyme inhibitors
Angiotensin II blockers
Aspirin
Diuretics
Per os antidiabetics
Insulin
Bivalirudin
Admission
ST-segment elevation myocardial infarction
Non–ST-segment elevation myocardial infarction
Unstable angina
Laboratory evaluation
Hematocrit, %
Platelets, 1,000 mm3
Creatinine clearance, ml/min
Creatinine clearance 60 ml/min
Platelet reactivity at Day 0 (PRU)
Values are n (%) or mean  SD.
CAD  coronary artery disease; NA  not applicable; PRU  platel
PR (in PRU) at the End-of-Treatment PeriodsTable 2 PR (in PRU) at the End-of-Treatment Periods
Endpoint n
Ticagrelor Least
Squares Estimates
(95% CI)
PR day 15 (pre-crossover) 43 34.1 (15.1 to 53.1)
PR day 30 (post-crossover) 42 32.1 (10.5 to 53.6)
Combined data (pre- and post-crossover) 85 32.9 (18.7 to 47.2)CI  confidence interval; PR  platelet reactivity; PRU  platelet reactivity unit(s).let inhibition achieved by clopidogrel. Using the VerifyNow
assay, we have previously reported a PR reduction of 160
PRU by prasugrel in patients post-PCI and presenting
HTPR while on clopidogrel, whereas a PR reduction of 260
PRU by ticagrelor has been described in patients character-
ized as nonresponders following 300 mg of clopidogrel
(15,17). The results of the present study are in the same line
of evidence.
lor¡Prasugrel
 22)
Prasugrel¡Ticagrelor
(n  22) p Value
9 (86.4) 18 (81.8) 1.0
.3 8.1 58.3 8.6 0.2
.9 2.8 30.3 6.1 0.1
2 (54.5) 10 (45.5) 0.8
5 (68.2) 10 (45.5) 0.2
5 (22.7) 5 (22.7) 1.0
5 (68.2) 13 (59.1) 0.8
3 (13.6) 1 (4.5) 0.6
0 (0) 3 (13.6) 0.2
1 (4.5) 0 (0) 1.0
3 (13.6) 3 (13.6) 1.0
0 (0) 0 (0) NA
1 (95.5) 20 (90.9) 1.0
8 (81.8) 18 (81.8) 1.0
2 (100) 21 (95.5) 1.0
3 (13.6) 4 (18.2) 1.0
1 (4.5) 0 (0) 1.0
6 (72.7) 15 (68.2) 1.0
5 (22.7) 4 (18.2) 1.0
2 (100) 22 (100) NA
6 (27.3) 7 (31.8) 1.0
3 (13.6) 3 (13.6) 1.0
1 (4.5) 0 (0) 1.0
1 (50.0) 5 (22.7) 0.1
8 (36.4) 11 (50.0) 0.5
7 (31.8) 3 (13.6) 0.3
7 (31.8) 8 (36.4) 1.0
.3 3.6 39.2 3.7 1.0
.1 64.1 243.0 56.4 0.06
.9 25.8 101.1 35.3 0.6
1 (4.5) 3 (13.6) 0.6
.4 34.4 280.3 38.1 0.8
ivity unit(s).
Prasugrel Least
Squares Estimates
(95% CI) n
Least Squares
Mean Difference
(95% CI) p Value
90.8 (72.3 to 109.4) 22 56.7 (83.3 to30.2) 0.001
111.4 (88.7 to 134.1) 20 79.3 (110.6 to48.0) 0.001
101.3 (86.8 to 115.7) 42 68.3 (88.6 to48.1) 0.001icagre
(n
1
61
27
1
1
1
2
1
2
1
2
1
39
207
95
277n
21
22
43
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conversion in the liver, irreversibly inhibits the P2Y12
receptor. By contrast, ticagrelor is a cyclopentyl-triazolo-
pyrimidine acting on the same receptor directly and revers-
ibly. In our study, ticagrelor “suppressed” PR to a very low
level, irrespectively of the initial pre-treatment level. By
contrast, PR reduction by prasugrel was less apparent,
particularly in patients originated from the upper quartile of
Figure 2 Platelet Reactivity (in PRU) by Treatment Sequence
Platelet reactivity is significantly lower in patients receiving ticagrelor compared
with prasugrel. Least squares estimates and 95% confidence intervals are pre-
sented. PRU  platelet reactivity unit(s).
Figure 3 Individual PR Values According to Treatment
Combined data for the pre- and post-crossover periods are depicted. Lines rep-
resent medians, and error bars represent interquartile range. Patients’ PR at
baseline in the upper quartile and the lower quartile are marked with asterisks
and open circles, respectively. Solid circles represent intermediate quartiles.
Only a minority of patients (2 of 11, 18.2%) remained in the upper quartile fol-
lowing ticagrelor, compared with 6 of 11 (50.0%) following prasugrel. HTPR 
high on-treatment platelet reactivity; PRU  platelet reactivity unit(s).baseline PR. A tentative explanation for the stronger anti-
platelet action of ticagrelor would be that although prasugrel
pharmacodynamic action has been reported not to be
affected by CYP2C19 and CYP2C9 polymorphism, we
cannot exclude the existence of other polymorphisms or
intrahepatic abnormalities affecting the extent of prasugrel
active metabolite in patients with HTPR, while leaving
unaffected the non–hepatic-dependent ticagrelor action
(20,21).
Ticagrelor and prasugrel were very effective in eliminating
HTPR while on clopidogrel. In previous studies, a poor
response rate to prasugrel has been reported in 0% of
patients in an ACS population, in 2.9% in diabetic patients
with CAD, and 7.5% in post-PCI patients with HTPR
while on clopidogrel (7,15,22). A high rate of prasugrel
resistance has been reported by Bonello et al. using the
vasodilator-stimulated phosphoprotein index, but most
likely, this was due (apart from the method used) to the
very early determination of PR, namely 6 to 12 h after the
loading dose (23). As for ticagrelor, the HTPR assessed
with the VerifyNow assay prevalence was 0% in 100
stable CAD patients 24 h post-loading (24) as well as
in 36 patients in the PLATO PLATELET substudy 2 to
4 h post–(peak) maintenance dose. These observations
were also confirmed in our study.
Clinical studies. In ACS patients with planned PCI, in
the TRITON–TIMI 38 study, prasugrel compared with
clopidogrel resulted in a better clinical outcome. The
primary efficacy endpoint of death from cardiovascular
causes, nonfatal myocardial infarction, or nonfatal stroke
occurred in 12.1% of patients receiving clopidogrel and
9.9% of patients receiving prasugrel (hazard ratio: 0.81; 95%
CI: 0.73 to 0.90; p  0.001), at a cost of higher rates of
TIMI major bleeding (13). In the PLATO trial in ACS
patients, ticagrelor compared with clopidogrel reduced the
primary endpoint of death from vascular causes, myocardial
infarction, or stroke from 11.7% to 9.8% (hazard ratio: 0.84;
95% CI: 0.77 to 0.92; p  0.001). Rates of major bleeding
were similar between ticagrelor and clopidogrel, though
major bleeding not related to coronary artery bypass grafting
was more frequent in the ticagrelor-treated patients (14). So
far, no direct clinical comparison of ticagrelor versus prasu-
grel has been performed. In an adjusted indirect comparison
meta-analysis of the TRITON–TIMI 38 and PLATO
trials, a head-to-head comparison of prasugrel and ticagrelor
showed no significant differences in overall death, myocar-
dial infarction, stroke, or their composite (25). Prasugrel
appeared more protective from stent thrombosis, while
causing more bleedings than ticagrelor.
In our small-sized and of short period pharmacodynamic
study, no patient exhibited a major adverse cardiovascular
event or a major bleeding event in either treatment group.
Ticagrelor was more frequently accompanied by other mild
side effects such as allergic reactions, dyspepsia, and new-
onset/worsening dyspnea.
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are only speculative. The demonstrated stronger antiplatelet
action of ticagrelor over prasugrel might affect the antiplate-
let agent choice in patients with ACS and HTPR while on
clopidogrel, especially in high-risk subgroups such as renal
failure patients (26). Similarly, a high thrombotic setting
like an ST-segment elevation myocardial infarction or
following stent thrombosis might represent attractive sce-
narios for choosing the stronger antiplatelet agent. The
effective treatment of HTPR while on clopidogrel by both
agents in our study may be reflected in the similar ischemic
event rates in the TRITON–TIMI 38 and PLATO trials.
In the post hoc analysis of the GRAVITAS (Gauging
Responsiveness with a VerifyNow P2Y12 Assay: Impact on
Thrombosis and Safety) trial a PRU208 was associated
with reduced death, myocardial infarction, and stent throm-
bosis rate, supportive of the principle “the lower PR the
better” (27). It is not known whether this is true for the very
low PR levels achieved by ticagrelor in our study. Recent
studies using the VerifyNow assay in clopidogrel-treated
patients have identified a pre-intervention PRU 189 and
a 1-month post-intervention PRU 85 as thresholds to
predict 30-day and 1-year bleeding outcome, respectively
(28,29). In our study, PR values attained were similar to
previous studies with prasugrel and ticagrelor (11,12,15,17),
though far below the previous thresholds, without observing
excessive bleeding. It is likely that the aforementioned
thresholds while using prasugrel and, particularly, ticagrelor
are of limited value for predicting bleeding events and new
thresholds for these agents need to be identified. Finally, our
study provides evidence that patients treated with prasugrel
can be directly switched to ticagrelor and vice versa, which
has not been previously investigated.
Study limitations. Only 1 method for platelet function
testing was used. However, the VerifyNow assay has been
found to correlate well with light transmittance aggregom-
etry, which is considered to be the “gold standard” method.
In the ONSET/OFFSET study assessing the antiplatelet
effects of ticagrelor and clopidogrel, the correlation coeffi-
cients for inhibition of platelet activation by light transmit-
tance aggregometry with inhibition percentage and PRU by
VerifyNow were robust (0.8483, p  0.0001; and 0.8631,
p  0.0001, respectively) (11). Pharmacokinetic samples
were not collected simultaneously with the samples for
platelet function analysis to allow assessment of relation-
ships between the two. The cutoff point of HTPR used has
only been evaluated during therapy with thienopyridines
and may differ for treatment with direct-acting P2Y12
inhibitors. The study was not powered to assess the rela-
tionship between pharmacodynamic data and clinical
outcomes.
Conclusions
In patients with ACS, exhibiting HTPR while on clopi-
dogrel 24 h post-PCI, ticagrelor produces a significantlyhigher platelet inhibition compared with prasugrel. Both
agents effectively treat HTPR. Further studies are needed to
elucidate whether the pharmacodynamic difference observed
translates into differences in clinical efficacy or safety.
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